Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Decreases By 10.0%

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 349,900 shares, a decrease of 10.0% from the March 31st total of 388,800 shares. Based on an average trading volume of 278,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 2.5% of the shares of the company are sold short.

Institutional Trading of Immix Biopharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC purchased a new stake in shares of Immix Biopharma in the 4th quarter valued at about $690,000. Tritonpoint Wealth LLC purchased a new stake in shares of Immix Biopharma in the 1st quarter valued at about $75,000. Jump Financial LLC purchased a new stake in shares of Immix Biopharma in the 4th quarter valued at about $128,000. Tocqueville Asset Management L.P. purchased a new stake in shares of Immix Biopharma in the 3rd quarter valued at about $41,000. Finally, Imprint Wealth LLC raised its holdings in shares of Immix Biopharma by 49.4% in the 4th quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock valued at $239,000 after acquiring an additional 11,400 shares in the last quarter. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

IMMX stock opened at $2.17 on Wednesday. The stock has a fifty day moving average of $2.87 and a 200-day moving average of $4.02. The company has a market capitalization of $57.29 million, a price-to-earnings ratio of -2.44 and a beta of 0.06. Immix Biopharma has a fifty-two week low of $1.40 and a fifty-two week high of $7.75.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Friday, March 29th. The company reported ($0.24) earnings per share (EPS) for the quarter. Equities analysts predict that Immix Biopharma will post -0.91 EPS for the current year.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.